Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. The results are from a pre-specified analysis of the Phase 3 VESALIUS-CV trial and were presented in a late-breaking science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. They were also simultaneously published in Circulation.

In a study of more than 12,000 high-risk patients, Repatha helped reduce the risk of dying by 20%. Treatment with Repatha led to meaningful reductions both in overall deaths and cardiovascular deaths in this pre-specified secondary analysis of VESALIUS-CV. By helping prevent major cardiovascular events, such as heart attacks and strokes, Repatha may extend life by helping patients avoid the serious health decline that can follow, contributing to fewer deaths overall. The reduction in deaths began to appear after approximately 1.5 years of treatment and continued through a median follow-up of 4.6 years.